Chemistry:Benzindopyrine
Benzindopyrine (INN; developmental code name IN-461), also known as pyrbenzindole or as 4-(1-benzyl-3-indolylethyl)pyridine, is a drug described as a "psychotherapeutic agent", "tranquilizer", and "ataractic" which was never marketed.[1][2][3][4][5] It is an indole derivative and an analogue of the neurotransmitter serotonin, though it is not a tryptamine.[1][3][5] The drug was studied in the treatment of anxiety and depression, but was found to be no more effective than placebo.[5] It is said to have central depressant effects in humans, though infrequently producing sleepiness and instead causing insomnia.[6] Benzindopyrine was first described in the scientific literature by 1959.[6][7][5][4] Methylindolylethylpyridine (IN-399; 4-(1-methyl-3-indolylethyl)pyridine), the analogue of benzindopyrine in which the 1-benzyl group has been replaced with a 1-methyl substitution, is also known.[3][7]
See also
References
- ↑ 1.0 1.1 The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014. ISBN 978-1-4757-2085-3. https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA135. Retrieved 11 May 2026.
- ↑ Martin Negwer: Organic-chemical drugs and their synonyms. Volume 2. Walter de Gruyter GmbH & Co KG. 1 August 2022. ISBN 978-3-11-261134-0. https://books.google.com/books?id=VWCKEQAAQBAJ&pg=PA888. Retrieved 11 May 2026.
- ↑ 3.0 3.1 3.2 Psychotropic Drugs and Related Compounds. National Institute of Mental Health. 1972. https://books.google.com/books?id=0rq7AAAAIAAJ&pg=PA121. Retrieved 12 May 2026.
- ↑ 4.0 4.1 "Investigational Drugs". American Journal of Health-System Pharmacy 20 (3): 145–151. 1 March 1963. doi:10.1093/ajhp/20.3.145. ISSN 1079-2082.
- ↑ 5.0 5.1 5.2 5.3 "The psychiatric use of pyrbenzindole: a double blind outpatient study". The Journal of New Drugs 2 (3): 167–172. 1962. doi:10.1177/009127006200200304. PMID 13904353.
- ↑ 7.0 7.1 "Preliminary study of the therapeutic and toxic effects of 4-(1-methyl-3-indolylethyl)pyridine hydrochloride in ambulatory patients with psychoneurosis". Toxicology and Applied Pharmacology 2 (3): 254–263. May 1960. doi:10.1016/0041-008x(60)90055-7. PMID 13801929.
 |  |
